Atom | Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)

Funder: National Institutes of Health

Funding Amounts: No budget cap; project period up to 3 years; total NIH/NIMH commitment for this and related NOFOs is $27M in FY 2026.

Summary: Supports early-stage clinical trials of novel pharmacologic or neuromodulatory device-based interventions for mental disorders, with a focus on understanding mechanisms and target engagement.

Key Information: Clinical trial required; strong preliminary data on target engagement is mandatory; limited submission—see eligibility.

Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)

Sign in to see full grant listing